“With IMS Health prescription data you get a behind-the-scenes insight into the pharmaceuticals market. It tracks the progress of recently launched products or, indeed, existing ones against the competition on a week by week basis.
Equally important, it accurately describes the demise of a drug once its patent protection has expired and generic competition enters the fray. For investment purposes then this information gives the user that crucial edge when analyzing a company ahead of its financial results.”
Alex Grosvenor
Investors Chronicle
Making investment decisions in the healthcare market? As an investor, getting the most accurate information is crucial but it also needs to cover the global market and be timely in its delivery. IMS gathers data from virtually every prescription distribution channel from wholesalers and hospitals to retailers and mail order firms. In many markets, IMS is the only information provider covering 100 percent of prescription distribution channels. With data as its lifeblood, IMS cultivates strong relationships with data suppliers, many of which use our insights in the company's own strategic planning.
Based on the key issues that the financial community faces, IMS has developed some valuable offerings and initiatives to meet a variety of needs:
- Evaluating company performance
- Assessing market potential
- Launch intelligence
- Patent expiration: when and where?
- Strategic alliances